RASGRP4

RASGRP4 is a calcium/cation-dependent, diacylglycerol/phorbol-ester-regulated guanine nucleotide exchange factor (GEF) that catalyzes GTP loading on Ras GTPases to drive differentiation, inflammation, and proliferation in hematopoietic and myeloid lineages (PMID:11956218, PMID:11880369). Biochemical reconstitution established it as a Ras-specific GEF bearing a DAG/phorbol-ester-binding C1 domain, and in myeloid cells phorbol-ester stimulation drives its membrane recruitment, elevates Ras-GTP, and supports cytokine-independent proliferation (PMID:11956218, PMID:11880369). Upstream, RASGRP4 acts in receptor-coupled signaling cascades: in neutrophils, GPCR engagement signals through PLCβ2/β3-generated diacylglycerol to RASGRP4, which provides the Ras input that activates PI3Kγ to generate PIP3 and drive chemokinesis and ROS production (PMID:22728827), and it operates downstream of the c-Kit/CD117 receptor in mast cell mediator programs (PMID:16605128). Through this GEF activity RASGRP4 controls late mast cell differentiation and granule maturation (PMID:11956218), hematopoietic prostaglandin D2 synthase expression and PGD2 output (PMID:12493770), and pro-inflammatory IL-1β and TNF-α expression, such that RasGRP4-null mice are protected from experimental colitis and arthritis (PMID:22511759). Its Ras-activating activity also makes it oncogenic: RASGRP4 behaves as a class I leukemogenic lesion cooperating with AML1 mutation (PMID:19350351), sustains ERK signaling and tumor growth in DLBCL (PMID:31409422), and serves as a key co-activator of KRAS-GTP in adrenocortical carcinoma (PMID:41792200). In macrophage biology, RASGRP4 regulates M1/M2 polarization and downstream inflammatory and fibrotic programs—via mTOR-STAT3 signaling driving M2 polarization downstream of CXCL8-CXCR2/PLCβ2 (PMID:40515877) and via an Aloxe3-dependent oxidative-stress axis promoting diabetic kidney injury and fibrosis (PMID:39656542, PMID:40662951). RASGRP4 GEF output is negatively regulated by the N-terminal domain of Galectin-3, which binds RASGRP4 and suppresses its GTP loading of N-Ras and H-Ras (PMID:18413234).

1. 2002 High

   Established the core biochemical identity of RASGRP4 as a cation-dependent, DAG/phorbol-ester-responsive Ras GEF, defining the activity all later functions depend on.

   Evidence In vitro Ras activation with recombinant protein plus phorbol-ester transfection assays; Ras-GTP pulldowns and membrane-localization imaging in 32D myeloid cells

   PMID:11880369 PMID:11956218

   Open questions at the time

   • Did not resolve which endogenous Ras isoform predominates in physiological cells
   • C1-domain DAG binding inferred functionally without structural characterization
2. 2002 High

   Linked RASGRP4 GEF activity to a cellular program by showing it drives terminal mast cell differentiation and controls hematopoietic PGD2 synthase/PGD2 output.

   Evidence Gain-of-function expression in HMC-1 cells with differentiation scoring; GeneChip, immunoblot, and siRNA knockdown in RBL-2H3 cells with PGD2 measurement

   PMID:11956218 PMID:12493770

   Open questions at the time

   • Transcriptional intermediaries between Ras activation and PGD2 synthase induction not mapped
   • Performed largely in cell lines rather than primary mast cells
3. 2005 Low

   Positioned RASGRP4 within a receptor-to-transcription axis, placing it downstream of c-Kit and upstream of MITF in mast cell mediator control.

   Evidence Pathway inference from isoform expression analysis and strain-dependent defective isoform production

   PMID:16605128

   Open questions at the time

   • No direct epistasis experiment described to order c-Kit, RASGRP4, and MITF
   • Conclusions drawn from expression correlation rather than perturbation
4. 2008 Medium

   Identified a negative regulator of RASGRP4, showing Galectin-3's N-terminal domain physically binds RASGRP4 and dampens its Ras-GTP loading.

   Evidence Co-immunoprecipitation, Ras-GTP pulldowns after Gal-3 shRNA or PMA activation, and ectopic Gal-3 N-terminal domain expression across cancer lines

   PMID:18413234

   Open questions at the time

   • Interaction interface on RASGRP4 not mapped
   • Single-lab interaction data without reciprocal structural validation
5. 2009 Medium

   Demonstrated RASGRP4 is oncogenic in vivo, functioning as a class I Ras-activating lesion that causes and cooperatively accelerates leukemia.

   Evidence Mouse bone marrow transplantation with retroviral RASGRP4 ± AML1 mutant, with disease monitoring and histopathology

   PMID:19350351

   Open questions at the time

   • Did not define the Ras isoform or downstream effectors driving transformation
   • Overexpression-based model may not reflect endogenous regulation
6. 2012 High

   Defined the physiological GPCR-to-PI3Kγ signaling role of RASGRP4 in neutrophils through genetic epistasis, establishing it as the GEF linking DAG to Ras-dependent PI3Kγ activation.

   Evidence RasGRP4-knockout and Ras-insensitive PI3Kγ knock-in mice with PIP3, PKB phosphorylation, chemokinesis, and ROS readouts

   PMID:22728827

   Open questions at the time

   • Direct biochemical demonstration of RASGRP4-PI3Kγ Ras handoff not isolated from cellular context
   • Which Ras isoform couples to PI3Kγ in neutrophils unresolved
7. 2012 High

   Showed RASGRP4 drives pro-inflammatory cytokine expression and is required for inflammatory disease in vivo, linking its signaling to colitis and arthritis pathology.

   Evidence RasGRP4-null mice with qRT-PCR for IL-1β/TNF-α and DSS colitis and K/BxN serum-transfer arthritis models

   PMID:22511759

   Open questions at the time

   • Cell-type-specific contribution to disease not dissected
   • Transcriptional mechanism connecting RASGRP4 to cytokine induction unmapped
8. 2016 Medium

   Extended RASGRP4 function beyond mast cells, showing it is needed in CD117+ dendritic cells and mast cells for them to act as NK cell accessory cells.

   Evidence RasGRP4-null mice, splenic DC isolation, and DC/MC-NK co-culture with LPS and IFN-γ readout

   PMID:26982501

   Open questions at the time

   • Molecular signal from RASGRP4 to NK-activating output not defined
   • Single-lab functional study
9. 2019 Medium

   Implicated RASGRP4 in solid-tumor/lymphoma signaling balance, showing it sustains ERK activation and proliferation while restraining JNK and oxidative stress in DLBCL.

   Evidence siRNA knockdown in SUDHL-4 cells with ERK/JNK immunoblot, proliferation/apoptosis/oxidative-stress assays, and xenografts

   PMID:31409422

   Open questions at the time

   • Mechanism by which RASGRP4 suppresses JNK not established
   • Knockdown-only loss-of-function in a single line
10. 2024 Medium

    Defined a role for RASGRP4 in macrophage and T-cell-driven kidney inflammation, linking it to M1 polarization, Th17 differentiation, and IL-17 signaling.

    Evidence RasGRP4-knockout mice in diabetes/ischemia-reperfusion injury models with flow cytometry and IL-17 pathway immunoblot

    PMID:39656542

    Open questions at the time

    • Direct GEF substrate connecting RASGRP4 to IL-17 signaling not shown
    • Macrophage versus T-cell contributions not separated genetically
11. 2025 Medium

    Resolved upstream and downstream macrophage circuitry, placing RASGRP4 in a CXCL8-CXCR2/PLCβ2 input driving M2 polarization via mTOR-STAT3 and a downstream Aloxe3 oxidative-stress/fibrosis axis.

    Evidence CXCR2 and PLCβ2 silencing, RASGRP4 knockdown/overexpression in THP-1 cells, mTOR-STAT3 immunoblot, xenografts; RasGRP4-KO DKD mice with transcriptomics and Aloxe3 colocalization/knockdown

    PMID:40515877 PMID:40662951

    Open questions at the time

    • How RASGRP4 GEF output engages mTOR-STAT3 versus Aloxe3 transcriptionally is not mechanistically bridged
    • Both axes characterized in single labs without reciprocal validation
12. 2026 Medium

    Quantitatively established RASGRP4 as a major co-activator of KRAS-GTP in carcinoma, accounting for activation that SOS alone cannot explain.

    Evidence ODE mathematical modeling, RasGEF expression panel, CRISPR depletion of RASGRP4, and tumor growth assays in nude mice

    PMID:41792200

    Open questions at the time

    • Direct biochemical KRAS exchange by RASGRP4 not reconstituted in this system
    • Modeling-derived conclusion in a single cell line

• It remains unresolved how RASGRP4 selectively engages different Ras isoforms and effector branches (PI3Kγ, ERK, mTOR-STAT3, IL-17) across cell types, and how its DAG/cation regulation and Galectin-3 inhibition are integrated structurally.
• No structure of RASGRP4 or its Ras/DAG/Galectin-3 complexes
• No unified model linking GEF activity to the divergent downstream effectors observed in different tissues